| Filed On | Filing |
|---|---|
| 06 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant +2 more
THIS LOAN AND SECURITY AGREEMENT is made and dated as of September 30, 2026, and is entered into by and among ROCKET PHARMACEUTICALS, INC., a Delaware corporation (“Company”), its Subsidiaries SPACECRAFT SEVEN, LLC, a Delaware limited li... |
| 15 Sep 2026 | 144 |
| 15 Sep 2026 |
Form 4: Wilson Martin, General Counsel
Sold 75,364 shares ($256K) |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure
FDA confirms pivotal efficacy population of 12 patients, including the first three treated under the modified protocol |
| 14 Sep 2026 | 144 |
| 11 Sep 2026 | 144 |
| 11 Sep 2026 | 144 |
| 02 Sep 2026 | 25-NSE |
| 27 Aug 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 20 Aug 2026 |
Form 4: Wilson Martin, General Counsel
Sold 631 shares ($2.13K) |
| 20 Aug 2026 |
Form 4: Shah Gaurav, CEO
Sold 2,293 shares ($7.75K) |
| 18 Aug 2026 | 144 |
| 18 Aug 2026 | 144 |
| 18 Aug 2026 | 144 |
| 17 Aug 2026 |
Form 4: Shah Gaurav, CEO
Sold 2,837 shares ($9.59K) |
| 17 Aug 2026 |
Form 4: Wilson Martin, General Counsel
Sold 3,493 shares ($11.8K) |
| 13 Aug 2026 |
Form 4: Stevens Christopher James, Chief Operating Officer
Sold 36,658 shares ($128K) |
| 13 Aug 2026 |
Form 4: Chaudhuri Sarbani, See Remarks
Sold 4,701 shares ($16.4K) |
| 13 Aug 2026 | 144 |
| 13 Aug 2026 | 144 |
Loading...
